Cancer Immunotherapy News and Research

RSS

New computational method improves analysis of single-cell transcriptomic data

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a new open-source computational method, dubbed Spectra, which improves the analysis of single-cell transcriptomic data.

5 Oct 2023

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Challenges associated with the development and design of neoantigen cancer vaccines.

5 Oct 2023

Research opens the door for better use of people's own immune system T cells to fight cancer

Using laboratory-grown cells from humans and genetically engineered mice, scientists at Johns Hopkins Medicine say they have evidence that modifying a specific protein in immune white blood cells known as CD8+ T cells can make the cells more robust, potentially opening the door for better use of people's own immune system T cells to fight cancer.

3 Oct 2023

Neoadjuvant immunotherapy shows promise in multiple cancer types

Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.

28 Sep 2023

$45M awarded to develop sense-and-respond implant technology for cancer treatment

The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.

26 Sep 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

Unlocking the secret soldiers: How dendritic cells could revolutionize cancer immunotherapy

A recent review in the journal Immunity delves into the crucial role of dendritic cells (DCs) in shaping T-cell responses in cancer, highlighting their importance in both priming anti-tumor immunity and in ongoing immune interactions within tumors. The findings underscore the potential of DCs as key targets for next-generation cancer immunotherapies.

18 Sep 2023

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.

14 Sep 2023

AACR Cancer Progress Report provides latest statistics on cancer research and treatment

Today, the American Association for Cancer Research (AACR) released the 13th edition of its annual Cancer Progress Report, which chronicles how basic, translational, and clinical cancer research and cancer-related population sciences-;primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)-;remain vitally important to improving health and saving lives.

13 Sep 2023

New research could help improve the effectiveness of immunotherapy for people with brain tumors

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive cancer that originates in the brain, does not.

1 Sep 2023

Universal approach could potentially expand CAR T cell therapy to all blood cancers

A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer.

31 Aug 2023

New microneedles could monitor melanoma therapy response

Patients with melanoma, the most concerning form of skin cancer in which pigment-producing cells start to grow out of control, can benefit from existing immunotherapies, but by far not all of them do.

21 Aug 2023

Anti-estrogenic therapies can suppress growth of ER-negative cancers

Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice models.

21 Aug 2023

Gut microbiota could affect the responsiveness and efficacy of cancer treatment

A vast number of microbes colonizes the human body to form an ecological community known as the microbiota. Microbiota are made up of bacteria, viruses, fungi, and archaea.

11 Aug 2023

Deep-learning technology could help scientists to develop personalized immunotherapies and vaccines

Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response.

9 Aug 2023

Researchers develop antibody drugs from tobacco plants for cancer treatment

For the first time in Thailand, lecturers at Chulalongkorn University's Faculty of Pharmaceutical Sciences have successfully developed antibody from tobacco plants with inhibitory effects on the growth of cancer cells in laboratory animals.

9 Aug 2023

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Researchers develop a novel cancer theranostic agent that can covert light energy to heat and in turn destroy cancer cells

4 Aug 2023

Surprising new role for a key immune regulator revealed

A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms.

3 Aug 2023

Tumor-derived GDF-15 suppresses immunotherapy response

Researchers evaluate the impact of tumor-derived GDF-15 on responses to anti-PD-1 immunotherapy.

26 Jul 2023

Three-pronged combination immunotherapy shows promise for pancreatic cancer patients

Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.

17 Jul 2023